In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Primary percutaneous coronary intervention versus pharmaco-invasive strategy versus facilitated percutaneous coronary intervention?

Session ST-elevation myocardial infarction 2013

Speaker Bernard Gersh

Event : ESC Congress 2013

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : ST-Elevation Myocardial Infarction (STEMI)
  • Session type : Symposium

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two columns page  

ST-elevation myocardial infarction 2013

Acute Coronary Syndromes (ACS)

 

4 papers were presented reviewing treatment options for ST elevation myocardial infarction.
The first talk was a splendid presentation was by Bernard Gersh and included time from first symptom to pre-hospital, door to balloon times in treatment of STEMI. The conclusion was things were going pretty well once a patient was in a cath lab and that treatment times were within the guidelines. The issue still to be resolved is getting patients quickly to a cath lab.
Often, even when there are cath labs or hospitals are available, there is often delay. To reduce myocardial damage it might be that fibrinolytic treatment could be started by paramedics to get early reperfusion.
Stefan James gave some insights into the Swedish care system with the SwedeHeart data. Considering the size of the country and the sparse population in large areas of the country, outcomes for patients in Sweden tend to be as good. Deepak Bhatt considered the part adjunctive therapies can play in improving outcomes. Although TAPAS was an encouraging study, TASTE was neutral and the value of thrombus removal, particularly by aspiration, seemed useful. Much of the presentation summarized the work done with the newer anticoagulants and antiplatelet agents.
Rounding off the session Michael Marber discussed new approaches that might be taken. The focus was on reducing myocardial damage with drugs in trials such as DETO2X-AMI and PRESERVATION 1, but the role of cell therapy might ultimately be a potential treatment to reverse myocardial damage.

References


747

SessionTitle:

ST-elevation myocardial infarction 2013

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are